Robert Weinstein - 25 Apr 2025 Form 4 Insider Report for PharmaCyte Biotech, Inc. (PMCB)

Reporting relationship: Director
Issuer ticker: PMCB
Reported as of: 25 Apr 2025
Net transaction value: -$34,425
SEC form: 4
Accepted by SEC: 12 Dec 2025, 17:08:04 UTC
Prior SEC filing: 18 Nov 2024
Next SEC filing: 03 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Robert Weinstein

Key filing fact

Robert Weinstein filed Form 4 for PharmaCyte Biotech, Inc. (PMCB) on 12 Dec 2025.

Key facts

This page summarizes Robert Weinstein's Form 4 filing for PharmaCyte Biotech, Inc. (PMCB).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Dec 2025, 17:08.

Change

Previous filing in this sequence was filed on 18 Nov 2024.
Current net transaction value: -$34,425.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001213709 Primary reporting owner

WEINSTEIN ROBERT

Relationship: Director
Address: C/O PHARMACYTE BIOTECH, INC., 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS
Signature: /s/ Robert Weinstein
Signature date: 12 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PMCB transaction

Common Stock

Award

Transaction value: $0
Shares: +75,000
Change %
Price: $0.000000
Shares after: 75,000
Date: 12 Dec 2025
Ownership: Direct

PMCB transaction

Common Stock

Tax liability

Transaction value: $34,425
Shares: -33,750
Change %: -45%
Price: $1.02
Shares after: 41,250
Date: 12 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PMCB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +63,233
Change %
Price: $0.000000
Shares after: 63,233
Date: 25 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 63,233
Exercise price: $1.22
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.

Footnote F2

The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Weinstein. This transaction is late due to an inadvertent administrative error and not any error of Mr. Weinstein.